Skip to content

Alumis Inc. ALMS Net margin

Net margin at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
15%+3.8pp
Amgen logo
AmgenAMGN
21%+3.6pp
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
-32,753.6%-35,519pp
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
-4,104.8%-7,304pp
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
-154.9%-182pp
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-612%+602pp

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.12B+739%
Enterprise value$3.1B+1,238%
P/S371.9×

Profitability

See full
Operating margin-5,364%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Calculated from Alumis Inc.’s reported figures.

Based on trailing twelve months.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s net margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alumis Inc.'s net margin?
Alumis Inc. (ALMS) reported net margin of -2,825.7% in Q1 2026.
What does net margin mean?
Net income as a percentage of revenue (trailing twelve months). The bottom-line profitability measure after all costs, interest, and taxes.